 NEW YORK, Nov. 18, 2020 GLOBE NEWSWIRE -- Prevail Therapeutics Inc. Nasdaq: PRVL, a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office USPTO on November 17, 2020 issued a composition of matter patent, U.S. Patent No. 10,837,028, with claims directed to the AAV vector used in PR001, Prevails experimental gene therapy program for the treatment of Parkinsons disease with GBA1 mutations PD-GBA and neuronopathic Gaucher disease nGD. The base patent term extends until October 3, 2038, excluding patent term extensions or coverage in additional related patent filings. 